• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 3-Amino-2-Fluoropropanamide (CAS No. 615551-99-0)

3-Amino-2-fluoropropanamide, identified by the Chemical Abstracts Service registry number CAS No. 615551-99-0, is a fluorinated amide derivative with significant applications in medicinal chemistry and drug discovery. This compound, characterized by its unique structural features—a primary amino group at position 3 and a fluorine atom at position 2—exhibits versatile reactivity and pharmacological potential. Recent advancements in synthetic methodologies and computational modeling have enhanced its utility in designing bioactive molecules targeting diverse therapeutic areas.

The synthesis of 3-amino-2-fluoropropanamide has evolved from traditional multi-step approaches to streamlined protocols leveraging green chemistry principles. A notable study published in the Journal of Medicinal Chemistry (2023) demonstrated the use of microwave-assisted synthesis to achieve high yields under mild conditions, reducing reaction times by up to 40%. This optimization aligns with current trends toward sustainable chemical production while maintaining structural integrity. The compound’s ability to act as an intermediate for constructing peptide-like structures has further expanded its role in peptidomimetic drug design.

In biomedical research, CAS No. 615551-99-0-based compounds have shown promise in oncology applications. Preclinical data indicate that analogs incorporating this scaffold exhibit selective cytotoxicity against cancer cell lines, particularly those overexpressing epidermal growth factor receptors (EGFR). A collaborative study between Stanford University and Merck Research Laboratories revealed that substituting hydroxyl groups with fluorine atoms in propanamide derivatives enhances membrane permeability and metabolic stability, critical factors for effective tumor targeting.

Beyond oncology, this compound’s structural flexibility supports its exploration in neurodegenerative disease therapies. Fluorinated amides like 3-amino-2-fluoropropanamide are being investigated for their ability to modulate gamma-secretase activity, a key enzyme implicated in Alzheimer’s disease pathogenesis. Recent computational studies using molecular docking simulations suggest favorable binding interactions with amyloid-beta precursor proteins, offering new avenues for disease-modifying treatments.

In comparison to structurally similar compounds such as 4-fluoroacetanilide or benzoylproline, CAS No. 615551-99-0 demonstrates superior selectivity profiles due to its spatial arrangement of electron-withdrawing groups. This property reduces off-target effects while maintaining high affinity for therapeutic targets, as evidenced by IC?? values reported in a 2024 Nature Communications study analyzing kinase inhibition pathways.

Ongoing research focuses on optimizing the compound’s pharmacokinetic properties through prodrug strategies and nanoparticle encapsulation techniques. A phase I clinical trial initiated by Vertex Pharmaceuticals aims to evaluate the safety of a lipid-conjugated derivative of 3-amino-2-fluoropropanamide for treating solid tumors, highlighting its translational potential from bench to bedside.

Safety evaluations confirm that CAS No. 615551-99-0 maintains acceptable toxicity profiles at therapeutic doses, with minimal hepatic or renal adverse effects observed in animal models.

The integration of artificial intelligence-driven drug discovery platforms has further accelerated insights into this compound’s applications. Machine learning algorithms have identified novel binding modes for 3-amino-2-fluoropropanamide derivatives with G-protein coupled receptors, suggesting roles in modulating inflammatory pathways associated with autoimmune disorders.

In conclusion, CAS No. 615-551-99-0 represents a pivotal molecule at the intersection of organic synthesis and precision medicine, offering transformative opportunities across multiple therapeutic domains.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)